Acadia Pharmaceuticals Inc Expected To Post Earnings Of 5 Cents A Share: Earnings Preview

Acadia Pharmaceuticals

07/05/2024 03:26

* ACADIA Pharmaceuticals Inc  ACAD.OQ   ACAD.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 8 for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
75.8% increase in revenue to $208.292 million from $118.46
million a year ago, according to the mean estimate from 19
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for ACADIA Pharmaceuticals
Inc is
for earnings of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ACADIA
Pharmaceuticals Inc is $30.00​, above​ its last closing price
of $17.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.29        0.30       0.28      Missed  -7.9
 Sep. 30 2023  -0.43       -0.43      -0.40     Beat    6.1
 Jun. 30 2023  -0.03       -0.08      0.01      Beat    112.1​
 Mar. 31 2023  -0.21       -0.21      -0.27     Missed  -25.8
 ​​Jan.        -0.24       -0.24      -0.26     Missed  -7
 1 0001                                                 
 Sep. 30 2022  -0.20       -0.19      -0.17     Beat    10.3​
 Jun. 30 2022  -0.24       -0.25      -0.21     Beat    15.2
 Mar. 31 2022  -0.67       -0.60      -0.33     Beat    45.1
 This summary was machine generated May 7 at 02:26 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)